Valuation: Delcath Systems, Inc.

Market Cap 551M 489M 457M 415M 783M 53.08B 789M 5.49B 2.14B 27.08B 2.07B 2.02B 87.06B P/E 2026 *
-106x
P/E 2027 * -198x
Enterprise Value 551M 489M 457M 415M 783M 53.08B 789M 5.49B 2.14B 27.08B 2.07B 2.02B 87.06B EV / Sales 2026 *
5.18x
EV / Sales 2027 * 4.17x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 01/10/2020
Director of Finance/CFO 47 01/05/2023
Chief Operating Officer 55 18/03/2024
Director TitleAgeSince
Chairman 62 16/02/2023
Director/Board Member 70 14/02/2020
Director/Board Member 60 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
-17.07%-34.08% - - 551M
-1.55%-2.40%-26.33%+1.70% 173B
-1.52%-0.61%-12.06%+13.71% 113B
-1.92%+0.23%-23.72%+5.10% 109B
+1.52%+1.45%-46.87%-10.58% 74.44B
-0.05%+2.27%+3.04%+71.12% 60.1B
+3.27%+7.25%+18.14%+67.16% 51.87B
-0.06%-0.76%-5.94%-31.19% 49.21B
-2.45%-3.57%-18.06%+15.34% 41.52B
-3.65%-3.59%+25.87%+0.37% 32.79B
Average -2.37%+0.62%-9.55%+14.75% 78.34B
Weighted average by Cap. -0.89%+0.42%-15.70%+12.03%

Financials

2026 *2027 *
Net sales 106M 94.28M 88.23M 79.97M 151M 10.24B 152M 1.06B 412M 5.22B 399M 390M 16.79B 132M 117M 110M 99.38M 188M 12.72B 189M 1.32B 512M 6.49B 495M 485M 20.87B
Net income -5.72M -5.08M -4.75M -4.31M -8.14M -552M -8.19M -57.08M -22.2M -281M -21.48M -21.01M -904M -3.39M -3.01M -2.81M -2.55M -4.82M -327M -4.85M -33.8M -13.15M -167M -12.72M -12.44M -536M
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Delcath Systems, Inc.